Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ORMP Oramed Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ORMP
Price (delayed)
$2.15
Market cap
$87.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.71
Enterprise value
$13.61M
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and
Highlights
The revenue has surged by 197% year-on-year
ORMP's debt has shrunk by 99% YoY and by 19% QoQ
Oramed Pharmaceuticals's gross margin has shrunk by 99% YoY
The gross profit has plunged by 98% YoY
Key stats
What are the main financial stats of ORMP
Market
Valuations
Earnings
Shares outstanding
40.85M
Market cap
$87.83M
Enterprise value
$13.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
44.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
Revenue
$2M
Gross profit
$13,000
Operating income
-$14.32M
Net income
-$28.24M
EBIT
-$35.89M
EBITDA
-$35.72M
Free cash flow
-$11.67M
Per share
Balance sheet
Liquidity
EPS
-$0.71
EPS diluted
-$0.71
Free cash flow per share
-$0.28
Book value per share
$3.45
Revenue per share
$0.05
TBVPS
$3.58
Total assets
$147.54M
Total liabilities
$7.65M
Debt
$301,000
Equity
$140.81M
Working capital
$125.98M
Debt to equity
0
Current ratio
23.94
Quick ratio
23.79
Net debt/EBITDA
2.08
Margins
Efficiency
Dividend
EBITDA margin
-1,786%
Gross margin
0.7%
Net margin
-1,411.9%
Operating margin
-716%
Return on assets
-17.3%
Return on equity
-18.2%
Return on invested capital
-38%
Return on capital employed
-25.3%
Return on sales
-1,794.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORMP stock price
How has the Oramed Pharmaceuticals stock price performed over time
Intraday
-5.7%
1 week
-3.59%
1 month
-6.93%
1 year
-2.71%
YTD
-11.16%
QTD
0.47%
Financial performance
How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$2M
Gross profit
$13,000
Operating income
-$14.32M
Net income
-$28.24M
Gross margin
0.7%
Net margin
-1,411.9%
The revenue has surged by 197% year-on-year
ORMP's net margin has shrunk by 191% YoY
Oramed Pharmaceuticals's gross margin has shrunk by 99% YoY
The gross profit has plunged by 98% YoY
Price vs fundamentals
How does ORMP's price correlate with its fundamentals
Growth
What is Oramed Pharmaceuticals's growth rate over time
Valuation
What is Oramed Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.62
P/S
44.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
The EPS has declined by 48% since the previous quarter
The P/B is 61% less than the 5-year quarterly average of 1.6 but 3.3% more than the last 4 quarters average of 0.6
The equity has contracted by 15% YoY and by 3.7% from the previous quarter
The revenue has surged by 197% year-on-year
Efficiency
How efficient is Oramed Pharmaceuticals business performance
The ROA has dropped by 60% since the previous quarter
The ROE has plunged by 54% from the previous quarter
Dividends
What is ORMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORMP.
Financial health
How did Oramed Pharmaceuticals financials performed over time
Oramed Pharmaceuticals's total liabilities has shrunk by 80% YoY and by 23% QoQ
The total assets has contracted by 28% YoY and by 5% from the previous quarter
ORMP's debt is 100% lower than its equity
Oramed Pharmaceuticals's debt to equity has shrunk by 100% YoY
ORMP's debt has shrunk by 99% YoY and by 19% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.